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Atrial ﬁbrillation (AF) can be cured by pulmonary vein antrum isolation(PVAI) in a substantial proportion of patients. The high
eﬃcacy of PVAI is partially undermined by a small but concrete periprocedural risk of complications, such as thromboembolic
eventsandbleeding.Acorrectmanagementofanticoagulationisessentialtopreventsuchcomplications.PerformingPVAIwithout
interruption of oral anticoagulation has been demonstrated feasible by our group in previous studies. Recently, we reported
that continuation of therapeutic warfarin during radiofrequency catheter ablation consistently reduces the risk of periprocedural
stroke/transientischemic attack without increasing the risk of hemorrhagic events.Of note, interrupting warfarin anticoagulation
mayactually increase the riskof strokeeven when bridged with heparin. The latter strategy is alsoassociatedwith an increased risk
ofminorbleeding. With regard to majorbleeding, we found no signiﬁcantdiﬀerence between patients with a therapeutic INR and
thosewho were bridged with heparin.Therefore, continuationoftherapeutic warfarin during ablationofAF appears to be thebest
anticoagulationstrategy. In this paper we summarize our experience with AF ablation without interruption of anticoagulation.
1.Introduction
Atrial ﬁbrillation (AF) is the most common sustained
arrhythmia in Western countries, with an estimated 30
million patients aﬀected by 2050 across United States and
Europe alone [1]. Atrial ﬁbrillation has a signiﬁcant impact
on morbidity mainly related to symptoms, heart failure, and
thromboembolic eventsand is the most frequent arrhythmic
causeofhospitaladmissionintheUSA[1–3].Inaddition,AF
is associated with excess mortality independently of throm-
boembolic complications [4]. To date, the most eﬀective
treatment for AF is radiofrequency catheter ablation, and
pulmonary vein antrum isolation (PVAI) is the mainstay
of such an approach [5]. The major drawback of catheter
ablation of AF consists in its potential risk of periprocedural
complications [6], with thromboembolic and hemorrhagic
complications being among the most common and insidious
ones [7, 8]. Despite the introduction of novel ablation
technologies, such as open irrigation catheters, and the
widespread use of systemic anticoagulation with heparin,
the risk of periprocedural thromboembolism remains not
negligible, reaching up to 2.8% in large series [6, 9]. With
these premises, the development of novel strategies able
to further decrease the risk of periprocedural thromboem-
bolism without increasing the risk of bleeding is crucial.
Oral anticoagulant therapy with warfarin is the current
standard of care for the treatment of AF, with a strikingly
favorable balance between thromboembolic protection and2 Cardiology Research and Practice
bleeding complications when adequate monitoring of inter-
national normalized ratio (INR) is achieved [10]. For years,
discontinuation of warfarin before ablation associated with
the periprocedural use of unfractioned and low molecular
weight heparin and bridging with warfarin after ablation
has been the most widespread anticoagulation protocol in
patientsundergoingcatheterablationofAF[5,11].Weﬁrstly
described the feasibility of AF ablation without interruption
of oral anticoagulation [12] and recently reported that this
approach is able to potentially abolish thromboembolic
complications without increasing the risk of bleeding [13].
Accordingly, AF ablation without interruption of anticoag-
ulation is nowadays the standard protocol in our center. In
this paper, we summarize our approach to anticoagulation
in patients undergoing AF ablation.
2.PreproceduralManagement
Patients eligible for catheter ablation of AF are started on
warfarin as outpatients, at least 2 months before the sched-
uled procedure. All patients receive weekly INR monitoring
duringthe4to6weeksprecedingtheprocedure,withatarget
INR of 2 to 3. Preprocedural transesophageal echocardio-
graphy (TEE) is performed only in patients showing sub-
therapeutic INR values in the month prior to the procedure.
Patients who demonstrate INR values consistently above 2 in
the month before the procedure are directly sent to ablation.
We routinely do not discontinue therapeutic warfarin before
the procedure.
3.PeriproceduralManagement
Ablation procedure is performed under general anesthesia.
Four venous accesses are obtained: two right and one left
femoral venous accesses, and one right internal jugular vein
access. Femoral venous accesses are usually obtained with
the Seldinger technique or with ultrasound guidance in
diﬃcult cases. The right internal jugular vein is accessed with
ultrasound guidance or under ﬂuoroscopic guidance with
a wire or a deﬂectable catheter advanced into this vein via
the right femoral vein sheath. A double transseptal puncture
is performed with the assistance of intracardiac echocar-
diography (ICE) [13, 14]. Before transseptal punctures, all
patients receive a bolus of unfractionated heparin (10,000
Units), followed by a noncontinuous infusion to maintain
an activated coagulation time (ACT) > 300 seconds. We
found important the addition of unfractionated heparin
to periprocedural therapeutic warfarin, since soft thrombus
can still be observed on the transeptal sheath or left atrial
catheters in patients with periprocedural therapeutic INR.
Radiofrequency energy is delivered with an open irri-
gated ablation catheter with a maximum temperature of
42◦C, power up to 45W , and ﬂow rate of 30cm 3/min.
Intracardiac echocardiography is continuously used to mon-
itor the electrode surface during ablation, to assist with
catheter positioning and identify coagulum formation, and
to monitor for complications including pericardial eﬀusion.
An esophageal temperature probe is always inserted to assist
with power titration during posterior wall ablation. At the
end of the left atrial ablation, we partially reverse heparin
anticoagulation with upto 40mg ofprotamine guidedby the
ACT and remove the sheaths when the ACT is less than 250
seconds.
With this approach there is no increased incidence
of major bleeding complications compared with bridging
therapy [13]. The majority of the major bleedings are related
tocardiactamponade,which canbeeﬀectivelymanagedwith
emergentpericardiocentesis, togetherwith heparin interrup-
tion and reversal with protamine, and warfarin reversal with
fresh-frozen plasma or prothrombin complex concentrate
[13]. All patients requiring pericardiocentesis are discharged
on anti-inﬂammatory agents for two weeks. If continued
signiﬁcant drainage or reaccumulation of the pericardial
eﬀusion occurs despite these measures, emergent open
surgical exploration is considered. Notably, there is also no
diﬀerence in rates of emergent surgical exploration between
patients with periprocedural therapeutic INR and those
who discontinue warfarin, although patients on therapeutic
anticoagulation are more likely to have a larger amount of
blood removed from their pericardium for stabilization and
require more blood transfusion units [13].
4.Postprocedural Management
All patients receive a single dose of aspirin (325mg) before
leaving the electrophysiology laboratory and continue their
warfarin dosage regimens to maintain a target INR of 2 to 3.
The beneﬁcial eﬀect of periprocedural therapeutic INR
possibly extends also to the postprocedural period. After
ablation the thromboembolic risk may be further increased
by the procedure-related endothelial damage, which may
activate the coagulation cascade and increase the risk of
thromboembolism [15].
Therefore, warfarin discontinuation may be associated
with an increased thromboembolic risk also in the postpro-
cedural period, since reachieving a therapeutic INR after the
procedure may take several days, and the risk of left atrial
thrombosis during AF is strikingly time dependent.
All patients are strictly monitored for outcome and
complications during overnight hospital stay, and on the
following day prior to discharge using symptom assessment,
serial neurological examinations, and puncture site checks.
All patients are instructed to call in case of any symptom
development and to send weekly transtelephonic electrocar-
diogram transmissions for the ﬁrst 5 months after ablation.
Progress of recovery and symptoms are assessed as well
by a dedicated nurse. In case of symptoms or suspected
complications patients are asked to seek medical attention
at either a local emergency department or our emergency
department or to follow up with their local physician. All
documentations from these visits are collected by our AF
center. Moreover, all patients present for followup 3 to
4 months after ablation with the electrophysiologist who
performed the procedure.
With regard to the out-of-hospital long-term antico-
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anticoagulation clinics with the aim of maintaining a stable
therapeutic INR level. We follow a standard, uniform, and
validated protocol of long-term postprocedural anticoag-
ulation management [16]. Brieﬂy, oral anticoagulation is
discontinued, regardless of the CHADS2 score, if patients
do not experience any recurrence of atrial tachyarrhythmias,
severe pulmonary vein stenosis (pulmonary vein narrowing
>70%), and severe left atrial mechanical dysfunction, as
assessed by transthoracic echocardiography.
Patients with a CHADS2 score ≥1 experiencing early
recurrence of AF are maintained on warfarin for at least
6 months. In these patients, warfarin is discontinued if
there is no AF recurrence in the last 3 months without
antiarrhythmic drugs, and aspirin 81 to 325mg is started.
In case of new AF recurrence after warfarin discontinuation
in patients with a CHADS2 score ≥1, oral anticoagulation is
restarted.
5.Discussion
Our approach to periprocedural anticoagulation has been
extensively validated in previous work [12, 13, 17]. In
particular, we found that a conventional anticoagulation
approach, which included warfarin discontinuation with
peri- and postprocedural bridging with unfractioned and
low-molecular-weight heparin actually increases the risk of
bleeding and thromboembolic complications, as compared
to no periprocedural interruption of oral anticoagulation
[12, 13, 17].
Our most recent report provides strong evidence that
performing AF ablation under therapeutic INR is a safe and
eﬀective approach to virtually abolish the risk of throm-
boembolic complications [13]. We reported a multicenter
prospective comparison of three anticoagulation protocols
in 9 centers performing the same ablation procedure. A
total of 6,454 patients were included in the study, of whom
2,488 underwent ablation with an 8-mm ablation catheter
and preprocedural warfarin discontinuation (Group 1),
1,348 underwent ablation with an open irrigated catheter
and preprocedural warfarin discontinuation (Group 2), and
2,618 underwent ablation with an open irrigated catheter
without preprocedural warfarin discontinuation (Group
3). Overall, periprocedural thromboembolic complications
occurred in 39 (0.6%) patients, with a rate of 1.1% in Group
1, and of 0.9% in Group 2. Notably, no patient of Group
3 experienced periprocedural thromboembolism (Figure 1).
These data support also the appropriateness of our approach
to TEE based on the intensity of anticoagulation in the
month preceding the procedure, especially considering that
1,178 (45%) Group 3 patients had persistent AF, and 498
(19%) long-standing persistent AF.
At multivariable analysis, which adjusted for age, gender,
coronary artery disease, type of AF, heart failure, diabetes,
hypertension, and prior stroke, the anticoagulation strategy
of ablation with a therapeutic INR was a strong inde-
pendent predictor of lower periprocedural thromboembolic
events (odds ratio 0.54, 95% conﬁdence interval 0.32 to
0.89, P = .017). With regard to bleedings, the pooled
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Figure 1: Complications of radiofrequency catheter ablation of
atrial ﬁbrillation in 6,454 patients referred to our institution
between 2002 and 2009. TIA = transient ischemic attack; 8-mm
= 8-mm nonirrigated ablation catheter; OIC = open irrigated
ablation catheter; oﬀ/on Coumadin = periprocedural discontinu-
ation/maintenance of therapeutic oral anticoagulant therapy with
warfarin (Coumadin). P from multiple comparison between OIC
on Coumadin and 8-mm and OIC oﬀ Coumadin: data from Di
Biase et al. [13].
rate of major bleeding complications (i.e., bleeding requir-
ing interventions including transfusions, hemopericardium,
hemothorax, and retroperitoneal bleeding) and pericardial
eﬀusion in patients who discontinued warfarin before the
ablation procedure (Groups 1 and 2) was 1.1%, whereas in
Group 3 was 0.8% (Figure 1). If also minor bleedings were
included,patientswhodiscontinuedwarfarinbeforeablation
procedure had a pooled rate of bleeding complications of
20.7%, while patients who were maintained on warfarin had
ar a t eo f4 . 8 % .
Translating such percentages into treatment eﬀects, the
netclinicalbeneﬁtassociated with AFablationwithoutinter-
ruption of oral anticoagulation is overwhelming (Figure 2),
with an estimated 170 thromboembolic or hemorrhagic
complications avoided every 1,000 patients ablated.
In the most recent survey on AF catheter ablation,
Cappato et al. reported thromboembolic and hemorrhagic
complicationratesin16,039patientsundergoingAFablation
between 2003 and 2006 in 521 centers distributed worldwide
[18]. All these patients had oral anticoagulant discontin-
uation before the ablation procedure. Accordingly, throm-
boembolic and bleeding complication rates in this large
survey were fairly consistent with that reported in Group 1
and 2 patients of our study [13, 18]. Based on our ﬁndings it
is estimable that, if periprocedural oral anticoagulation was
not discontinued in all patients included in the survey, more
than 2,700 thromboembolic or hemorrhagic complications
would have been avoided worldwide from 2003 to 2006.
Therefore, there are cogent data supporting the beneﬁt of AF
ablation without discontinuation of oral anticoagulation.4 Cardiology Research and Practice
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Figure 2: Beneﬁts of atrial ﬁbrillation ablation without interrup-
tion of oral anticoagulation. TIA = transient ischemic attack; 8-
mm oﬀ Coumadin (referent group) = 8-mm nonirrigated abla-
tion catheter with periprocedural discontinuation of therapeutic
oral anticoagulant therapy with warfarin (Coumadin); OIC oﬀ
Coumadin = open irrigated ablation catheter with periprocedural
discontinuation of therapeutic oral anticoagulant therapy with
Coumadin; OIC on Coumadin = open irrigated ablation catheter
with periprocedural maintenance of therapeutic oral anticoagulant
therapy with Coumadin: data from Di Biase et al. [13].
Since the acute reversal of the anticoagulant eﬀect of
warfarin is possible only through infusion of fresh coagula-
tion factors, we routinely type- and cross-match all patients,
so that packed red blood cells and fresh frozen plasma
are readily available for infusion in case of hemorragic
complications. If the preprocedural INR is above 3.5, we
partially reverse the anticoagulant eﬀect with one to two
units of fresh frozen plasma.
Of interest, the strategy of ablation under therapeutic
INR could also be more cost-eﬀective compared to bridging
therapy with enoxaparin, which is expensive and may be
inconvenient for many patients.
6.Conclusions
Radiofrequency catheter ablation of AF without discon-
tinuation of oral anticoagulation signiﬁcantly reduces the
risk of thromboembolic and minor bleeding complications.
Maintenance of periprocedural therapeutic INR should be
considered the anticoagulation strategy of choice among
patients submitted to catheter ablation of AF.
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